Diabetes

Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, attenuates diabetic nephropathy, insulin resistance and hypertension and extends life span via up regulation of its target gene, 18/November/2017, 8.03 am
Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, attenuates diabetic nephropathy, insulin resistance and hypertension and extends life span via up regulation of its target gene, 18/November/2017, 8.03 am 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor…

read more

Molecular therapy for glucose homeostasis and TIIDM: Butylphthalide (3-n-butylphthalide or NBP), found in celery oil,  increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/November/2017, 5.59 am
Molecular therapy for glucose homeostasis and TIIDM: Butylphthalide (3-n-butylphthalide or NBP), found in celery oil,  increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/November/2017, 5.59 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that…

read more

Molecular therapy for middle aged TIIDM patients: Fidarestat,an alodose reductase inhibitor used to control diabetic complications, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 15/November/2017, 5.26 am
Molecular therapy for middle aged TIIDM patients: Fidarestat,an alodose reductase inhibitor used to control diabetic complications, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 15/November/2017, 5.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA; and Laboratory…

read more

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Victoza/Saxenda, a drug used in the treatment of TIIDM and Obesity,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 15/September/2017, 5.14 am
Molecular therapy for TIIDM and obesity-associated metabolic deficits: Victoza/Saxenda, a drug used in the treatment of TIIDM and Obesity,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 15/September/2017, 5.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Atorvastatin, a lipid-lowering agent, decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 14/November/2017, 6.41 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: Atorvastatin, a lipid-lowering agent, decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 14/November/2017, 6.41 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Molecular therapy for Metabolic diseases: Victoza/Saxenda, a glucagon-like peptide-1 receptor agonist that promotes insulin secretion, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene,  14/November/2017, 6.23 am
Molecular therapy for Metabolic diseases: Victoza/Saxenda, a glucagon-like peptide-1 receptor agonist that promotes insulin secretion, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene,  14/November/2017, 6.23 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published,…

read more
Start Typing